Syntron Bioresearch Revenue and Competitors
Estimated Revenue & Valuation
- Syntron Bioresearch's estimated annual revenue is currently $7.8M per year.
- Syntron Bioresearch's estimated revenue per employee is $251,000
Employee Data
- Syntron Bioresearch has 31 Employees.
- Syntron Bioresearch grew their employee count by 11% last year.
Syntron Bioresearch's People
Name | Title | Email/Phone |
---|---|---|
1 | President | Reveal Email/Phone |
Syntron Bioresearch Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is Syntron Bioresearch?
Founded in 1986, Syntron is a research, development and manufacturing company specializing in advanced rapid in vitro immunodiagnostic test systems. Syntron Bioresearch is licensed as a Medical Device Establishment by the United States Food and Drug Administration (FDA) and the State of California Department of Health Services, Food and Drug Branch, and has 510(k) approval for many of its products.
keywords:N/AN/A
Total Funding
31
Number of Employees
$7.8M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Syntron Bioresearch News
2022-04-20 - Análisis del informe de investigación de mercado de ...
Syntron Bioresearch, Inc Teco Diagnostics Thermo Fisher Scientific, Inc Tosoh Bioscience, Inc Diametra DiaSorin S.p.AMM.
2022-04-20 - Analyse de la croissance future du marché mondial des ...
Syntron Bioresearch, Inc, Teco Diagnostics, Thermo Fisher Scientific, Inc Androidfun.fr...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.8M | 31 | -9% | N/A |
#2 | N/A | 31 | 3% | N/A |
#3 | $5.2M | 31 | 19% | N/A |
#4 | $5M | 31 | 19% | N/A |
#5 | $5M | 31 | 7% | N/A |